The effectiveness of a digital shared decision-making tool in hormonal contraception during clinical assessment: study protocol of a randomized controlled trial in Spain by de Molina-Férnandez, Maria Inmaculada et al.
STUDY PROTOCOL Open Access
The effectiveness of a digital shared
decision-making tool in hormonal
contraception during clinical assessment:
study protocol of a randomized controlled
trial in Spain
Maria Inmaculada de Molina-Férnandez1, Laia Raigal-Aran1* , Miriam de la Flor-Lopez2, Paula Prata3,
Isabel Font-Jimenez1, Francesc Valls-Fonayet4, Gemma March-Jardi5, Ramon Escuriet-Peiro6 and
Lourdes Rubio-Rico1
Abstract
Background: Decision-making tools represent a paradigm shift in the relationship between the clinician and the
user/patient. Some of their advantages include patient commitment, the promotion of preferences and values, and
increased treatment adherence.
This study protocol aims to assess the effectiveness of a decision-making tool in contraception (SHARECONTRACEPT)
concerning: a) Improvement in counselling on hormonal contraception at the medical consultation, measured in terms
of decreasing decisional conflict and improving knowledge of available contraceptive options; b) Improvement in
adherence to treatment measured in terms of: persistence in the chosen treatment, compliance with dose or
procedure of use, and ability to deal with incidents related to the use of the contraceptive method; and decreasing
unwanted pregnancies and voluntary interruption of pregnancy.
The SHARECONTRACEPT tool, developed by previous phases of this project, is available at: http://decisionscompartides.
gencat.cat/en/decidir-sobre/anticoncepcio_hormonal/
Methods/design: A longitudinal, prospective-type, randomized, controlled community clinical trial, carried out in the
clinical contraceptive counselling units of 6 autonomous regions in Spain, with an experimental group and a control
group. Description of the intervention: The health professionals participating will be randomly assigned to one of the
two groups. Clinicians assigned to the experimental group will perform contraceptive counselling assisted by
SHARECONTRACEPT, and those of the control group will follow the conventional contraceptive counselling
provided in their clinical unit.
It is planned to study 1708 users (control group n = 854 and intervention group n = 854), recruited from
women who attend the consultations of the health professionals. The selected users will be followed up for
one year. The data will be collected through ad-hoc questionnaires, and validated instruments for measuring
decisional conflict and adherence to treatment.
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Discussion: The results of this study protocol will offer evidence of the effectiveness of a shared decision-
making tool, SHARECONTRACEPT, which may prove a useful tool for users and professionals to promote
adherence to contraceptive methods.
Trial registration: Clinical Register number ISRCTN5827994. Date: 15/04/2019 (Retrospectively registered)
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Background
In Spain, nine out of ten women of childbearing age,
between 15 and 49 years, report that they have had
sex, at some time, and two out of ten report having
had sex without using any method of contraception.
In other words, some two million women would currently
be exposed to an unwanted pregnancy in our country
(SEC) [1]. In this regard, in 2015 a report was published
that stated that approximately 35% of pregnancies in Spain
were unwanted (some 190,000 unwanted pregnancies/
year) [2].
Half of these unwanted pregnancies in Spain end in
voluntary termination (VTP), 93,131 in 2016, according
to a report on these terminations by the Spanish Ministry
of Health. The report highlights a decline in VTPs in recent
years and although it would be nice to think that this is due
to better use of contraceptives, the fact that only 10.4% of
total VTPs were due to medical reasons is worrying [3].
Also, it should not be forgotten that the role being played
by emergency (post-coital) contraception to reduce un-
wanted pregnancies and the subsequent reduction in the
rate of VTPs is not known; according to the latest survey of
2018, presented by the SEC, 30% of respondents reported
resorting to emergency contraception, at some time [1].
The condom is the most popular form of contraceptive
in Spain: it is used by 29.6% of the population, compared
with 17.3% of women who use combined hormonal con-
traceptives (CHC), the most commonly used hormonal
method of contraception across all age brackets. The
population continues to rely, therefore, on the condom, a
good way to avoid possible contagion by sexually trans-
mitted diseases (STDs), but one that is not a very effective
contraceptive in practice when compared with other hor-
monal methods due to its inconsistent and/or incorrect
use [1]. Each year, eighteen out of every 100 women con-
dom users get pregnant during their first year of use com-
pared to nine out of 100 women users of CHC per year,
according to Pearl indices corresponding to each method,
as published recently by the World Health Organization
(WHO) [4].
In the last 30 years, new hormonal contraceptives have
been added to the range of existing contraceptive devices,
drugs or technologies. Most of these additions have
involved modifications or a variety of alternatives to oral
hormonal contraception, the best-known and most widely
used, but also to other methods such as the progestogen
pill (used by 0.1%), combined injectable contraceptives
(used by 0.2%), patches (used by 0.7%), and the combined
hormonal vaginal ring (used by 2.9%). Long-acting revers-
ible contraception (LARC) methods, including intrauter-
ine devices (IUDs) and the subdermal implant, are the
most effective as regards avoiding unwanted pregnancies
(Pearl index for implants, the Levonorgestrel IUD and the
copper IUD of 0.05, 0.2 and 0.8–2 pregnancies per 100
women/year, respectively) [5]. Based on the latest results
of the SEC, in 2018, an increase can be seen in the last
year in the use of LARC (9.6% of total users), with respect
to the 2016 survey (7.7% of total users) [1, 6].
According to the results of the latest survey on the use
of contraceptives in Spain, 1% used an implant, 4.3% had
a hormonal IUD and 4.3% had a copper IUD [1]. These
methods, in addition to their excellent cost-effectiveness
ratio and comfort and safety for the health of women,
are highly efficient as they do not influence non-com-
pliance with or the misuse of the method by the user.
This aspect differentiates them from other hormonal
methods, which, while highly effective in theory, their
effectiveness is reduced by the lack of adherence to
treatment [1, 4, 7].
The term adherence includes two concepts: compli-
ance with doses (taken correctly in accordance with the
drug posology) and persistence in the duration of the
prescribed treatment (constant use of treatment over
time) [8]. The lack of adherence to contraceptive treat-
ments generally compromises their effectiveness and
results in many of the unwanted pregnancies and
VTPs, with an estimated annual cost of approximately
80 million euros to the national health system [2].
In a recent review, it was found that in Spain, non-
compliant use of contraceptives among users of CHC is
common, between 65 and 70% of users forget or delay a
pill more than once a month, but moreover, 18% did not
use any additional method subsequently and 43% were
distressed by the possibility of getting pregnant that
month, showing a lack of skills and knowledge as to how
to act in the event of an oversight or non-compliance
[8]. In addition, there is a high dropout rate from CHC
within 12 months of the start of treatment, with figures
close to 50%, which are due to the onset of side effects
and/or the lack of adherence to treatment [9].
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The low use of LARC is not influenced by the lack of
adherence, but could be explained by problems related
to: a lack of knowledge of such methods, accessibility to
them, and the bleeding pattern they present that is not
accepted by all women, as they are not informed of it
[1, 4, 5, 10]. In this regard, recent SEC survey data show
that 45.6% of women acknowledged that their doctor or
midwife did not offer them the contraceptive option of
a LARC during their counselling consultation, despite the
fact that in several of the autonomous communities par-
ticipating in the population survey, this type of long-acting
contraception is financed wholly or in part [1, 10].
The data set out above show the need to encourage
the population of potential users of contraceptive methods
to get access to balanced and objective information on the
different contraceptive methods based on the latest scien-
tific evidence to help them choose the most suitable to their
health status and their personal situation [4]. Dehlendorf,
the author of an interesting review of how contraceptive ad-
vice should be given, stresses the need for clinicians, before
such demand, to establish a close and trusting relationship
with users.
In recent years, the patient has acquired a more active
and responsible role in relation to the management of
their health and in the clinical practice. On a daily basis,
patients and healthcare professionals face situations in
which decisions related to the diagnostic process and/or
different treatment options should be taken jointly [11, 12].
To facilitate this, shared decision-making tools (SDMT)
have been developed, that promote discussion between
patients and healthcare professionals concerning the
various treatment options [11–13].
The purpose of this study protocol is to evaluate the
effectiveness of an SDMT in open access online digital
hormonal contraception during contraceptive counselling
consultation, according to the needs of the population.
Methods/design
Study framework
The SDMT in hormonal contraception, SHARECON-
TRACEPT, was previously devised by the authors De
Molina, Rubio and De la Flor.
In August 2018, it was published on the “Decisions
Compartides” website of the Department of Health of the
Generalitat (Government) of Catalonia, in Spanish, Catalan
and English: http://decisionscompartides.gencat.cat/en/
decidir-sobre/anticoncepcio_hormonal/index.html).
Below, we set out how it was produced, as we consider
it relevant as a reference framework for the study:
For the design of the SHARECONTRACEPT SDMT,
the criteria of the International Patient Decision Aid
Standards (IPDAS), an international group of researchers
and health professionals set up in 2003 to determine the
standard criteria for the development of SDMT in view of
their increasing occurrence, were followed [13, 14]. These
criteria, grouped in a checklist of 30 items, establish the
three blocks for inclusion in SDMTs: clinical content, de-
velopment process and evaluation of effectiveness [13, 15].
For the SHARECONTRACEPT development process,
the stages described by the National Health System (NHS)
Agency for Evaluation, Technology and Performance were
followed for SDMT evaluation and validation [15]. Then,
the development process is described in stages (Study
framework flowchart of the design of SHARECONTRA-
CEPT, Fig. 1).
Clinical trial of SHARECONTRACEPT
Hypothesis
Advice on hormonal contraception at the physician’s
office, with the support of the SHARECONTRACEPT
SDMT, encourages dialogue and the exchange of informa-
tion between the woman and the clinician, which can help
select a contraceptive method more in accordance with
her preferences, needs, priorities and characteristics, thus
improving adherence to the method of choice.
Aims and objectives
The purpose of this project is to evaluate the effectiveness
of the SHARECONTRACEPT SDMT during contracep-
tive counselling in six autonomous communities of Spain
1. To determine whether the use of
SHARECONTRACEPT improves adherence to
the chosen contraceptive treatment, in relation
to compliance with dose or method of use and
persistence in the duration of the prescribed
treatment,
2. To assess whether SHARECONTRACEPT increases
the ability to cope with incidents related to the use
of the method,
3. To assess the social impact of using
SHARECONTRACEPT in relation to decreasing
unwanted pregnancies and voluntary termination
of pregnancy (VTP),
4. To analyse whether SHARECONTRACEPT
decreases the woman’s conflict in view of the
choice of contraceptive method,
5. To assess whether the use of SHARECONTRACEPT
helps clinicians to better understand the various
hormonal contraceptive options available and their
characteristics (risks, benefits and consequences), and.
6. To analyse whether the use of SHARECONTRACEPT
changes the pattern of use of hormonal contraception
in the population towards more effective methods.
Design
The research is approached as a longitudinal, prospective
community clinical trial. While in the conventional format
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of clinical trials allocation is performed on the participat-
ing subjects themselves, in the community format, clusters
are assigned to which the units of analysis belong.
In this research, the clusters are the professionals of
the Clinical Units of the six participating Spanish
autonomous communities: Madrid, Aragon, Galicia, the
Basque Country, Valencia and Catalonia (see Fig. 2). The
units of analysis are the women attending the con-
sultation of the professionals between 1 July 2019 and
30 June 2020.
Clusters sample
Firstly, the clusters were selected. The researchers
responsible for each of the six autonomous communities
in Spain recruited them by means of convenience
sampling. During the first quarter of 2019, professional
clinicians giving contraceptive counselling (gynaecologists,
midwives, family doctors and/or nurses) from the different
Spanish autonomous communities participating were in-
vited to take part. One hundred and sixty-four (164) pro-
fessionals agreed to participate and they were randomly
Fig. 1 Study framework of the development of the Shared Decision-Making Tool following the stages described by the National Health System
(NHS) Agency for Evaluation, Technology and Performance
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assigned using the EPIDAT program (single sampling), to
one of two groups:
1- Experimental Group (EG), professionals who will
perform counselling with the support of the
SHARECONTRACEPT SDMT, and
2- Control group (CG), professionals who will perform
clinical counselling as they had until then
(conventional contraceptive counselling).
Starting from this context, it was decided to create the
Web page: Sharecontracept.com, through which the pro-
fessionals can easily access the three different environ-
ments in which they are to participate.
1-virtual campus In order, insofar as possible, to
standardize the procedure to be followed given that the
different professional profiles and broad geographical
spread, the Foundation of the Rovira i Virgili University
in Tarragona (Spain) designed a 60-h online course for
the professionals involved in the project.
This course is to be implemented prior to starting the
fieldwork. There are two courses, one for the CG and
the other for EG. The professionals of each group will
receive an email with a link in order to access the corre-
sponding SHARECONTRACEPT virtual course with a
username and a password. Once inside the course, and
after a brief presentation, they will be asked to perform a
test of knowledge on contraception at the beginning and
at the end of the course, to assess whether SHARECON-
TRACEPT improves the knowledge of the professionals
who use it. After the first test, the system will allow
them access to the rest of the course environment,
where, among others, they will find forums through
which they can contact the research team.
In addition, through documents and videos, they will
get access to the contents of the different subjects (see
Table 1), depending on whether they are professionals
assigned to EG (they will be able to view the six subjects
from the beginning) or CG (during the fieldwork they
will only be able to view subjects 2 and 6, although they
will be able to get access to the rest once sample collec-
tion has finished).
2- user registration Having reviewed the course con-
tents, the professional will be requested to register with
the data collection platform.
3-platform Finally, via this icon, access to the data col-
lection base is granted, using a username and personal
password, to start inputting cases (units of analysis).
Unit analysis sample
Sample size
In a second stage the units of analysis are recruited. A
sample of 1708 women is established (Table 2). The cal-
culation was performed using the EPIDAT program to
test hypotheses in a model of comparison of proportions
in independent groups. A possible loss of 25% of the
sample is estimated, and so by applying the correction
factor where R is the expected proportion of losses, the
following sample size is finally envisaged:
Sample selection criteria The sample will be selected
from the women attending the practice of one of the
professionals from either CG or EG requesting counsel-
ling on contraception or when such need is found du-
ring the stipulated period (1 July 2019 to 30 June 2020)
and who fulfil the following inclusion criteria: have
completed their primary education and be competent in
Spanish and/or Catalan (the languages of SHARECON-
TRACEPT, although it is also in English); be between 16
and 49 years of age, have internet access, and agree to
participate voluntarily in the study. Women are ex-
cluded who wish to have children within one year of the
date of consultation or have a history of: stroke,
acute myocardial infarction, thrombosis, breast
cancer (< 5 years), liver cirrhosis or liver tumour.
Fig. 2 Map of participating communities where the clusters were
selected. Created by the author
Table 1 Moodle course table of contents
Theme 1 The shared decisions model
Theme 2 The SHARECONTRACEPT project
Theme 3 Which are the WHO’s eligibility criteria
Theme 4 Keys to giving good counselling
Theme 5 Videos with examples of how to counsel with the
support of SHARECONTRACEPT
Theme 6 Instructions on how to implement the information
collection platform of the SHARECONTRACEPT Project
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Information collection questionnaires Information on
each of the women will be collected at four times during
a year, from two online questionnaires developed ad
hoc: an in-person survey and a telephone survey (to be
conducted 3 times: at one month, at 6 months, and one
year following the in-person consultation).
The main variable is adherence to treatment (compliance
with the dose and method of administration and persist-
ence in the duration of the prescribed treatment) and the
secondary variables include the woman’s sociodemographic
characteristics, her medical, obstetrical and gynaecological
history, her contraceptive method, decisional conflict, and
variables of the professional (see Table 3).
The statistical approach will consist of a set of biva-
riate and multivariate descriptive analyses and the appli-
cation of logistic regression models to determine the
extent to which the likelihood of changing birth control
method and the likelihood of choosing one particular
method are linked to certain specified variables. Losses
are considered as women that do not complete the
follow-up of the protocol to which they were assigned or
that do not to remain until the end of the analysis.
Study limitations
The fact that the two groups (EG and CG) may come
into contact at the same health centre or unit could result
in professionals who must continue to provide counselling
in a conventional manner (CG) potentially modifying how
they behave if they find out about or get access to SHARE-
CONTRACEPT due to comments by their EG peers. To
avoid this insofar as possible, during training EG will be
asked to keep absolute confidentiality.
Different autonomous communities, different sexual
and reproductive healthcare policies, different funding
schemes for contraceptive methods, different profes-
sionals giving counselling with different levels of training
(midwives, nurses, gynaecologists and family physicians)
could be limitations, and so these variables must be duly
taken into account when analysing the results.
Discussion
It is recommended, during counselling on contraception,
to use a shared decision-making approach focusing on
ascertaining the user’s values and preferences, which
helps facilitate qualified information on each contraceptive
method and according to their needs in order to promote
adherence to the chosen contraception and advise in the
event of the occurrence of side effects, among others [16].
Before choosing a particular method there are aspects
related to the potential user and the characteristics of
each of the methods that must be clearly defined. To
begin with, there is a need for a good anamnesis includ-
ing the woman’s age, previous knowledge of the subject,
Table 2 Study sample size calculated using the EPIDAT
program
Power (%) Sample size* (+ correction factor for expected losses)
EG CG Total
80.0 854 854 1708
Sample sizes to apply the χ2 test with Yates continuity correction
*An α risk of 0.05 and a β risk of 0.2 (80% power) are assumed, standard values
in such studies
Table 3 Variables collected in the study
Main variable Adherence to treatment:
• Compliance with dose and method of
administration and
• Persistence in the duration of the prescribed
treatment
Secondary variables Woman’s sociodemographic characteristics:
• Age
• Level of education
• Occupation
• Marital status/partner
Contact details
• Telephone
• Telephone 2
Medical history:
• Smoker
• HBP
• Uterine malformations
Obstetric and gynaecological history:
• Menstrual pattern
• Miscarriage
• VTP
• Living children
Contraceptive method
• Contraceptive method considered by the
patient before counselling
• Experiences with other methods
• Woman’s attitude towards compliance
(Morisky-Green treatment adherence test)
• Contraceptive finally chosen
• Incidents with the chosen method
• Incident management
Decisional conflict
The woman’s decisional conflict in view of
the choice of contraceptive method
(O’Connor Scale)
https://decisionaid.ohri.ca/eval_dcs.html
And of the professional:
• Satisfaction with the counsellor or clinician with
the use of the digital SDMT (Likert scale)
• Test of knowledge prior to and after fieldwork
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information about her sexual partner, the purpose of
contraception, personal preferences and predisposing
factors for poor compliance in accordance with the
method [17]. Regarding the method, the woman must
be familiar with the main features of the existing methods;
their effectiveness, side effects and safety, reversibility,
possible non-contraceptive benefits, ease or complexity of
use, impact on intercourse, and price, among others [18].
Dehlendorf warns that many women express dissatis-
faction with the counselling they receive from clinicians
[16], and other studies have found that clinicians show
inaccurate knowledge of contraceptive methods and/or
possess outdated information [16, 19, 20]; it would also
appear that the decision made by women is strongly in-
fluenced by the mention or recommendation of specific
methods by the clinicians providing counselling, in a pa-
ternalistic healthcare environment [11, 16]. SDMTs have
been created to change this. Specifically, SHARECON-
TRACEPT has been devised to help clinicians and users
in the processes of learning, counselling and choice of
the contraceptive method that best suits each person
and situation.
This project enables testing by users and clinicians in
the daily practice and within the health system whether
this SDMT in hormonal contraception is effective, giving
them all an opportunity to review it and comment on it,
which are key aspects of the development process of an
SDMT [15].
Abbreviations
CG: Control group; CHC: Combined hormonal contraception; EG: Experimental
group; IPDAS: International Patient Decision Aid Standards; IUD: Intrauterine
devices; LARC: Long-Acting Reversible Contraception; SDMT: Shared Decision-
Making Tools; SEC: Sociedad Española de Contracepción (Spanish Society of
Contraception); STD: Sexually transmitted diseases; VTP: Voluntary termination
of pregnancy; WHO: World Health Organization
Acknowledgements
The authors gratefully acknowledge the support of the study participants
and partner organizations.
Study group members from the project PI18/00915 who are involved in the
implementation of the clinical trial: Dr. Cristina Martinez Bueno1, Ms. Maria
Dolores Martinez-Romero2, Dr. Lucia Martinez-Villarejo3, Ms. Montserrat
Moharra-Frances4, Prof Jose Cruz Quilez-Conde5, Ms. Anna Rodriguez-
Martinez6, Dr. Federico Villagrasa-Rocher7, Ms. Demetria Patricio-Peña 8, Ms.
Dolores Creus-Pujol9.
1Institut Català de la Salut. Barcelona. Spain.
2Dirección general de asistencia sanitaria SERGAS. Santiago de Compostela.
Spain.
3Midwifery training unit. Madrid. Spain.
4Agència de Qualitat i Avaluació Sanitàries. Generalitat de Catalunya.
Barcelona. Spain.
5Hospital Universitario de Basurto. Bilbao. Spain.
6Institut Català de Salut Barcelona. Generalitat de Catalunya. Spain.
7Centro de Salud Sexual y Reproductiva. Departamento de Alcoi. Conselleria
de Sanitat. Generalitat Valenciana. Spain.
8Institut Català de la Salut. ASSIR Reus-Altebrat, Tarragona. Spain.
9Institut Català de la Salut. ASSIR Lleida. Spain.
Authors’ contributions
IMF, MFL, LRR, IFJ, FVF, and GMJ obtained funding for, conceived, designed
and coordinated the study. LRA, REP and PP conceived the study and
participated in its design, performance, coordination and community
engagement. All authors have given their final approval of the version
submitted for publication.
Funding
This study has undergone peer-review by the funding body Instituto de
Salud Carlos III - ISCIII (Spanish Government), in the 2018 call under the
Health Strategy Action 2013–2016, within the National Research Programme
oriented to Societal Challenges, within the Technical, Scientific and Innovation
Research National Plan 2013–2016, with reference PI18/00915, co-funded with
European Union European Regional Development Fund (ERDF) funds.
These sources of funding did not play a role in the Spanish study design,
data collection, study management, data analysis, interpretation of the data,
writing of the report, or in the decision to submit the report for publication.
The authors declare that they have no competing interests.
Availability of data and materials
The study is ongoing.
Data will be available when the study ends (31/12/2021).
Ethics approval and consent to participate
Participants will be informed about the content, purpose, and procedure of
the study by means of a written form of informed consent. No negative
impact on the study participants is expected.
The study will be conducted in accordance with the principles of the
Helsinki Declaration, and will follow Spain’s best practice guidelines (Buena
Práctica Clínica). Data confidentiality will be protected under the Spanish law
governing the protection of personal data (Ley Orgánica 3/2018 de
Protección de Datos de Carácter Personal).
Ethics approval was obtained from the Ethics Committee of Institut
d’Atenció Primària Jordi Gol (reference coder: P18/208) and from the Institut
d’Investigacions Sanitàries Pere Virgili (reference code CEIM: 186/2018). These
Ethical Approvals cover all the participating sites included in this study.
Consent for publication
Not applicable as the manuscript does not contain any individual person’s
data which is not from the research group.
Competing interests
The authors declare that they have no competing interests.
Author details
1Nursing Department, Campus Catalunya, Universitat Rovira i Virgili, Av/
Catalunya, 35, 43002 Tarragona, Spain. 2Medicine Department, Universitat
Rovira i Virgili, C/ Dr. Mallafrè Guasch, 4, 43005 Tarragona, Spain. 3Escola
Superior de Enfermagem do Porto, Portugal, Rua Bernardino de Almeida,
4200-072 Porto, Portugal. 4Universitat Rovira i Virgili, Campus Catalunya,
Universitat Rovira i Virgili, Av/ Catalunya, 35, 43002 Tarragona, Spain. 5Institut
Català de la Salut, Primary Care Unit. CAP Jaume I, C/ Jaume i, 45-49, 43005
Tarragona, Spain. 6Àrea d’Atenció Sanitària. Gerència de Salut i Atenció
Integrada, Servei Català de la Salut | Generalitat de Catalunya, Travessera de
les Corts, 131-159 | Pavelló Ave Maria, |08028 Barcelona, Spain.
Received: 16 August 2019 Accepted: 29 August 2019
References
1. Sociedad Española de Contracepción. Encuesta Nacional 2018 sobre la
Anticoncepción en España [Internet]. 2018. http://sec.es/presentada-la-encuesta-
nacional-2018-sobre-la-anticoncepcion-en-espana/. Accessed 1 Jul 2019.
2. Lete I, Hassan F, Chatzitheofilou I, Wood E, Mendivil J, Lambrelli D, et al. Direct
costs of unintended pregnancy in Spain. Eur J Contracept Reprod Health Care.
2015;20:308–18. https://doi.org/10.3109/13625187.2015.1028617.
3. Ministerio de Sanidad, Consumo y Bienestar Social. Interrupción Voluntaria
del Embarazo 2016. http://www.mscbs.gob.es/profesionales/saludPublica/
prevPromocion/embarazo/docs/IVE_2016.pdf. Accessed 1 Jul 2019.
4. Organización Mundial de la Salud. Departamento de Salud Reproductiva e
Investigaciones Conexas editor. Recomendaciones sobre prácticas
seleccionadas para el uso de anticonceptivos. Tercera edición ed.
Ginebra (Suiza): Organización Mundial de la Salud; 2018. https://www.
Molina-Férnandez et al. BMC Public Health         (2019) 19:1224 Page 7 of 8
who.int/reproductivehealth/publications/family_planning/SPR-3/es/.
Accessed 3 Jun 2019.
5. McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE
project round up. Clin Obstet Gynecol. 2014;57:635–43. https://doi.org/10.1
097/grf.0000000000000070.
6. Observatorio de Salud Sexual y Reproductiva de la SEC. Estudio poblacional
sobre el uso y la opinion de los metodos anticonceptivos en Epaña. Madrid:
Sociedad española de Contracepción. 2016. http://sec.es/area-cientifica/
observatorio/documentos-observatorio/. Accessed 4 Jun 2019.
7. Cristóbal Garcia I. Anticoncepción con métodos reversibles de larga duración.
Matronas Profesión 2015;16:50–51. https://www.federacion-matronas.org/wp-
content/uploads/2018/01/articulo-especial-anticoncepcion.pdf. Accessed 19
Jun 2019.
8. Adarve-Hidalgo E, Falguera G, Seguranyes G. Adherencia y cumplimiento
del método anticonceptivo hormonal oral. Revista Matronas. 2016;17:1–34.
9. Lete I, Pérez-Campos E, Correa M, Robledo J, de la Viuda E, Martínez T, et al.
Continuation rate of combined hormonal contraception: a prospective
multicenter study. J Women's Health. 2012;21:490–5. https://doi.org/10.1
089/jwh.2011.2967.
10. Federación de Planificación Familiar Estatal (FPFE). El acceso de las mujeres
a la anticoncepción en las comunidades autónomas. 2016. http://www.fpfe.
org/wp-content/uploads/2017/02/DEF_Acceso-Anticoncepc-CC.AA_..pdf.
Accessed 1 Jul 2019.
11. Ruiz-Azarola A, Perestelo-Pérez L. Participación ciudadana en salud:
formación y toma de decisiones compartida. Informe SESPAS 2012. Gac
Sanit. 2012;26:158–61. https://doi.org/10.1016/j.gaceta.2011.10.005.
12. Peralta Munguía L. La participación del paciente en la toma de decisiones en
las consultas de atención primaria. Universidad de Cantabria; 2011. https://
www.tesisenred.net/handle/10803/10705#page=1. Accessed 17 Jul 2019.
13. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et
al. Shared decision making: a model for clinical practice. J Gen Intern Med.
2012;27:1361–7. https://doi.org/10.1007/s11606-012-2077-6.
14. Volk RJ, Llewellyn-Thomas H, Stacey D, Elwyn G. Ten years of the
international patient decision aid standards collaboration: evolution of the
core dimensions for assessing the quality of patient decision aids. BMC Med
Inform Decis Mak. 2013;13:S1. https://doi.org/10.1186/1472-6947-13-S2-S1.
15. Perestelo-Pérez, L. Pérez-Ramos, J. Rivero-Santana, A. Carballo-González, D,
Serrano Aguilar, P: Manual con criterios de evaluación y validación de las
Herramientas de Ayuda para la Toma de Decisiones. Ministerio de Sanidad,
Servicios Sociales e Igualdad. Gobierno de España. 2013. http://ipdas.ohri.ca/
SESCS_2013_HATD.pdf. Acessed 1 Jun 2019.
16. Dehlendorf C, Krajewski C, Borrero S. Contraceptive counseling: best
practices to ensure quality communication and enable effective
contraceptive use. Clin Obstet Gynecol. 2014;57:659–73. https://doi.org/10.1
097/GRF.0000000000000059.
17. Lete I, de la Viuda E, Gómez MÁ, Haimovich S, Martínez M. Nuevas
recomendaciones para el consejo anticonceptivo basadas en el estilo de
vida. Resultados de un estudio Delphi. Progresos de Obstetricia y
Ginecología. 2015;58:4–13. https://doi.org/10.1016/J.POG.2014.07.011.
18. Soriano Fernández H, Rodenas García L, Moreno Escribano D: Criterios de
Elegibilidad de Métodos Anticonceptivos: Nuevas Recomendaciones. Revista
Clínica de Medicina de Familia. 2010;3:206–216. http://scielo.isciii.es/scielo.
php?script=sci_arttext&pid=S1699-695X2010000300009. Accessed 2 Jun, 2019.
19. Dehlendorf C, Levy K, Ruskin R, Steinauer J. Health care providers’
knowledge about contraceptive evidence: a barrier to quality family
planning care? Contraception. 2010;81:292–8. https://doi.org/10.1016/j.
contraception.2009.11.006.
20. Schreiber CA, Harwood BJ, Switzer GE, Creinin MD, Reeves MF, Ness RB.
Training and attitudes about contraceptive management across primary
care specialties: a survey of graduating residents. Contraception. 2006;73:
618–22. https://doi.org/10.1016/j.contraception.2006.01.014.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Molina-Férnandez et al. BMC Public Health         (2019) 19:1224 Page 8 of 8
